Efficacy and safety of tenofovir in preventing mother-to-infant transmission of hepatitis B virus: a meta-analysis based on 6 studies from China and 3 studies from other countries

Table 1 Baseline characteristics of patients in the trials included in the meta-analysis

Study	Country	Study design	Treatment regimen	No. of patients	Pregnancy time when tenofovir was started (w)	Age (mean ± SD, y)	HBV DNA (log10 IU/ml)	NOS score
Greenup AJ [20]	Austria	Cohort	Tenofovir 300 mg daily	58	30–32	30 ± 8.5	7.94 ± 0.78	7
			Lamivudine 100 mg daily	52		28 ± 5.3	7.72 ± 0.61
			No medication	20		28 ± 5	8 ± 0.04
Chen HL [36]	China	Cohort	Tenofovir 300 mg daily	62	32	32.41 ± 3.12	8.25 ± 0.45	9
Chen HL [36]			No medication	56		32.45 ± 3.2	8.24 ± 0.35
Pan CQ [37]	China	RCT	Tenofovir 300 mg daily	97	30–32	27.4 ± 3.0	8.2 ± 0.5	NA
Pan CQ [37]			Usual care	100		26.8 ± 3.0	8.0 ± 0.7
Celen MK [38]	Turkey	Cohort	Tenofovir 300 mg daily	21	18–27	28.2 ± 4.1	8.28	6
Celen MK [38]			Untreated	24		26.9 ± 2.9	8.31
Kochaksaraei GS [39]	Canada	Cohort	Tenofovir 300 mg daily	23	28 (21–32)	30(28–34)	7.7(3.2–8.1)	6
Kochaksaraei GS [39]			Untreated	138		32(29–36)	2.3(1.6–3.1)
Chen WJ [40]	China	Cohort	Tenofovir 300 mg daily	30	23.9 ± 1.9	28.67 ± 5.71	≥6.0	7
			Telbivudine 600 mg daily	79		31.13 ± 6.27	≥6.0
			Untreated	44		29.86 ± 5.05	≥6.0
Wan JY [41]	China	Cohort	Tenofovir 300 mg daily	74	28	28.5 ± 4.2	7.69 ± 0.54	8
Wan JY [41]			Untreated	42		27.9 ± 4.0	7.57 ± 0.48
Qi LW [42]	China	Cohort	Tenofovir 300 mg daily	54	6	27.5 ± 3.6	7.01 ± 0.98	7
Qi LW [42]			Untreated	32		26.4 ± 3.1	6.51 ± 1.03
Deng J [43]	China	Cohort	Tenofovir 300 mg daily	20	10	26.15 ± 2.56	NR	7
Deng J [43]			Untreated	20		28.32 ± 2.45	NR

Abbreviation: SD standard deviation, NR not reported, NA not available, NOS Newcastle-Ottawa scale

ISSN: 1471-230X